Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster

Table 4 Relative risk of cardiovascular outcomes following herpes zoster (time after infection)

	IRR (95% CI) of outcome
Time interval after first incident of herpes zoster	Myocardial infarction	Stroke	MACE	VTE
30 days	1.81 (0.91, 3.63)	0.95 (0.35, 2.62)	1.23 (0.68, 2.23)	1.60 (0.63, 4.05)
45 days	1.66 (0.90, 3.06)	0.97 (0.42, 2.25)	1.13 (0.67, 1.89)	1.58 (0.71, 3.52)
60 days	1.48 (0.84, 2.64)	1.36 (0.72, 2.59)	1.19 (0.76, 1.87)	2.13 (1.13, 4.02)
90 days	1.31 (0.78, 2.20)	1.02 (0.55, 1.89)	0.93 (0.60, 1.42)	2.13 (1.22, 3.72)

CI confidence interval, IRR incidence rate ratio, MACE major adverse cardiovascular events, VTE venous thromboembolic event

ISSN: 1478-6362